Repurposing of Clinically Approved Poly-(ADP-Ribose) Polymerase Inhibitors for the Therapy of Sepsis

Author(s)

Santos, Sidneia Sousa ^[1] ; Colo Brunialti, Milena Karina ^[1] ; Soriano, Francisco Garcia ^[2] ; Szabo, Csaba ^[3] ; Salomao, Reinaldo ^[1]

Affiliation

^[1] Univ Fed Sao Paulo, Paulista Sch Med, Div Infect Diseasses, Sao Paulo - Brazil

^[2] Univ Sao Paulo, Fac Med, Lab Med Res, Sao Paulo - Brazil

^[3] Univ Fribourg, Fac Sci & Med, Chair Pharmacol, Fribourg - Switzerland

• Document type: Review article
• Source: Shock; v. 56, n. 6, p. 901-909, DEC 2021.
• Web of Science Citations: 1

Abstract

Sepsis' pathogenesis involves multiple mechanisms that lead to a dysregulation of the host's response. Significant efforts have been made in search of interventions that can reverse this situation and increase patient survival. Poly (ADP-polymerase) (PARP) is a constitutive nuclear and mitochondrial enzyme, which functions as a co-activator and co-repressor of gene transcription, thus regulating the production of inflammatory mediators. Several studies have already demonstrated an overactivation of PARP1 in various human pathophysiological conditions and that its inhibition has benefits in regulating intracellular processes. The PARP inhibitor olaparib, originally developed for cancer therapy, paved the way for the expansion of its clinical use for nononcological indications. In this review we discuss sepsis as one of the possible indications for the use of olaparib and other clinically approved PARP inhibitors as modulators of the inflammatory response and cellular dysfunction. The benefit of olaparib and other clinically approved PARP inhibitors has already been demonstrated in several experimental models of human diseases, such as neurodegeneration and neuroinflammation, acute hepatitis, skeletal muscle disorders, aging and acute ischemic stroke, protecting, for example, from the deterioration of the blood-brain barrier, restoring the cellular levels of NAD(+), improving mitochondrial function and biogenesis and, among other effects, reducing oxidative stress and pro-inflammatory mediators, such as TNF-alpha, IL1-beta, IL-6, and VCAM1. These data demonstrated that repositioning of clinically approved PARP inhibitors may be effective in protecting against hemodynamic dysfunction, metabolic dysfunction, and multiple organ failure in patients with sepsis. Age and gender affect the response to PARP inhibitors, the mechanisms underlying the lack of many protective effects in females and aged animals should be further investigated and be cautiously considered in designing clinical trials. (AU)

• FAPESP's process: 18/18418-5 - DNA repair, oxidative stress and metabolic dysfunction in sepsis - investigation of possible therapeutic target
• Grantee: Sidneia Sousa Santos
• Support Opportunities: Scholarships in Brazil - Post-Doctoral
• FAPESP's process: 17/21052-0 - Sepsis: mechanisms, therapeutic targets and epidemiology
• Grantee: Reinaldo Salomão
• Support Opportunities: Research Projects - Thematic Grants